Cargando…
Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis
INTRODUCTION: After stage 3 CKD, the risk of adverse cardiovascular events increased significantly. Therefore, we performed a meta-analysis to investigate the cardiovascular protective effect of SGLT2 inhibitors in patients with stage 3/4 CKD with different baseline kidney function or underlying dis...
Autores principales: | Li, Ning, Zhou, Guowei, Zheng, Yawei, Lv, Dan, Zhu, Xiangjun, Wei, Ping, Zheng, Min, Liu, Shijia, Zhou, Enchao, Sun, Wei, Zhang, Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754287/ https://www.ncbi.nlm.nih.gov/pubmed/35020750 http://dx.doi.org/10.1371/journal.pone.0261986 |
Ejemplares similares
-
Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Li, Ning, et al.
Publicado: (2021) -
Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
por: Li, Ning, et al.
Publicado: (2022) -
SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
por: Mavrakanas, Thomas A., et al.
Publicado: (2023) -
The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
por: Noel, J. Ariana, et al.
Publicado: (2022) -
A Novel Nomogram Based on a Competing Risk Model Predicting Cardiovascular Death Risk in Patients With Chronic Kidney Disease
por: Li, Ning, et al.
Publicado: (2022)